Halozyme Therapeutics Inc

Russell Investments Canada Limited Announces Monthly Distributions for Exchange Traded Fund Series ("ETF Series") and Exchange Traded Funds ("ETFs")

Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon™ Technology

Halozyme Appoints David Ramsay as Interim Chief Financial Officer

Breakout Ventures Launches Fund III with $114M to Continue Building the Future Powered by Science

U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma